RxDoctor Payments Data

Julian Thomas, MD

Cardiovascular Disease · Morehead City, NCNPI 1417926221

Payments from drug & device makers

$11,972in general payments, 2019–2025

Across 72 payments — averaging $166.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$11K
  • Novartis$448
  • Johnson & Johnson$162
  • Nevro Corp.$120
  • E.r. Squibb & Sons, L.L.C.$77
  • Sanofi-aventis U.S. LLC$71
  • plus $368 from 12 others

What the payments were for

  • Food & beverage$1,352100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,972 in reported general payments places this provider in the 70th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$150,435
Medicare patients
841
Services billed
1,736

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban230$214,726
XareltoRivaroxaban83$70,850
EntrestoSacubitril/Valsartan33$26,326
BrilintaTicagrelor28$19,873
Repatha SureclickEvolocumab13$10,618
Dofetilide21$6,244
Repatha SyringeEvolocumab11$5,790
Metoprolol Succinate272$2,731
Atorvastatin Calcium166$1,564
ClopidogrelClopidogrel Bisulfate130$1,415
Isosorbide Mononitrate ErIsosorbide Mononitrate109$1,194
Losartan Potassium97$977
Ranolazine ErRanolazine11$937
Metoprolol Tartrate133$887
Diltiazem 24hr Er (Cd)Diltiazem Hcl76$844

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$59$214,726230 claims
Johnson & JohnsonXarelto$162$70,85083 claims
NovartisEntresto$448$26,32633 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Morehead City

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →